Everett Harris & Co. CA lowered its position in Organon & Co. (NYSE:OGN – Free Report) by 17.0% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 40,297 shares of the company’s stock after selling 8,235 shares during the period. Everett Harris & Co. CA’s holdings in Organon & Co. were worth $771,000 as of its most recent SEC filing.
A number of other large investors have also made changes to their positions in OGN. Teachers Retirement System of The State of Kentucky increased its holdings in shares of Organon & Co. by 250.3% in the fourth quarter. Teachers Retirement System of The State of Kentucky now owns 80,128 shares of the company’s stock worth $1,155,000 after acquiring an additional 57,255 shares in the last quarter. GAMMA Investing LLC increased its stake in Organon & Co. by 29.5% during the 1st quarter. GAMMA Investing LLC now owns 3,387 shares of the company’s stock worth $64,000 after purchasing an additional 772 shares in the last quarter. Wedmont Private Capital acquired a new stake in Organon & Co. during the 1st quarter worth approximately $214,000. Douglas Lane & Associates LLC lifted its stake in Organon & Co. by 35.3% in the first quarter. Douglas Lane & Associates LLC now owns 488,304 shares of the company’s stock valued at $9,180,000 after buying an additional 127,529 shares in the last quarter. Finally, Ballentine Partners LLC boosted its holdings in shares of Organon & Co. by 11.9% in the first quarter. Ballentine Partners LLC now owns 18,553 shares of the company’s stock valued at $349,000 after buying an additional 1,969 shares during the period. Institutional investors own 77.43% of the company’s stock.
Organon & Co. Price Performance
NYSE OGN opened at $17.61 on Friday. The firm’s 50 day moving average is $19.98 and its 200-day moving average is $20.14. The company has a quick ratio of 1.17, a current ratio of 1.64 and a debt-to-equity ratio of 60.05. The company has a market capitalization of $4.53 billion, a PE ratio of 4.53, a price-to-earnings-growth ratio of 0.79 and a beta of 0.84. Organon & Co. has a 12-month low of $10.84 and a 12-month high of $23.10.
Organon & Co. Announces Dividend
The business also recently announced a quarterly dividend, which was paid on Thursday, September 12th. Investors of record on Friday, August 16th were issued a dividend of $0.28 per share. The ex-dividend date was Friday, August 16th. This represents a $1.12 annualized dividend and a yield of 6.36%. Organon & Co.’s payout ratio is presently 28.79%.
Wall Street Analyst Weigh In
A number of equities research analysts recently commented on the stock. Evercore ISI upgraded shares of Organon & Co. to a “strong-buy” rating in a report on Wednesday, September 18th. JPMorgan Chase & Co. lowered Organon & Co. from a “neutral” rating to an “underweight” rating and boosted their price target for the company from $18.00 to $20.00 in a report on Friday, September 6th.
Read Our Latest Research Report on OGN
About Organon & Co.
Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.
Recommended Stories
- Five stocks we like better than Organon & Co.
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- How to Choose Top Rated Stocks
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
- 3 Warren Buffett Stocks to Buy Now
- MarketBeat Week in Review – 10/14 – 10/18
Want to see what other hedge funds are holding OGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organon & Co. (NYSE:OGN – Free Report).
Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.com's FREE daily email newsletter.